Scenic Biotech Appoints Renowned Neurology Drug Development Leader Dr. Judith Walker as Chief Medical Officer
- Dr. Walker joins to lead Scenic’s transition into clinical development and shape its clinical strategy
- Lead program SC6177 is advancing toward the clinic with a first-in-class approach to restoring lysosomal function, a key driver of multiple neurodegenerative disease
Amsterdam, The Netherlands — 10 September 2026: Scenic Biotech (“Scenic” or “the Company”), a neurometabolic company whose function-first genomics engine has identified a first-in-class therapy to restore lysosomal function, a core driver of neurodegeneration in many diseases, today announced the appointment of Dr. Judith Walker, MD, as Chief Medical Officer (CMO).
